Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M140,772Revenue $M44,408Net Margin (%)11.2Z-Score2.2
Enterprise Value $M155,051EPS $1.9Operating Margin %15.3F-Score5
P/E(ttm))25.6Cash Flow Per Share $0Pre-tax Margin (%)13.8Higher ROA y-yY
Price/Book2.010-y EBITDA Growth Rate %8.2Quick Ratio1.0Cash flow > EarningsY
Price/Sales3.25-y EBITDA Growth Rate %-1.6Current Ratio1.4Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %8.7ROA % (ttm)3.9Higher Current Ratio y-yN
Dividend Yield %3.6Insider Buy (3m)0ROE % (ttm)6.5Less Shares Outstanding y-yN
Payout Ratio %89.0Shares Outstanding M2,649ROI % (ttm)4.2Gross Margin Increase y-yN

Gurus Latest Trades with SNY

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SNYPRIMECAP Management 2014-06-30 Add0.03%$51.23 - $54.54
($53.08)
$ 53.290%Add 21.59%3,011,646
SNYScott Black 2014-06-30 Reduce-0.39%$51.23 - $54.54
($53.08)
$ 53.290%Reduce -27.57%178,985
SNYJohn Hussman 2014-06-30 Sold Out -0.09%$51.23 - $54.54
($53.08)
$ 53.290%Sold Out0
SNYScott Black 2014-03-31 Buy 1.4%$47.77 - $53.63
($50.64)
$ 53.295%New holding, 247100 sh.247,100
SNYJames Barrow 2014-03-31 Add0.39%$47.77 - $53.63
($50.68)
$ 53.295%Add 22.72%27,790,116
SNYCharles Brandes 2013-12-31 Add0.2%$48.75 - $54
($51.57)
$ 53.293%Add 18.29%2,013,300
SNYMario Gabelli 2013-12-31 Reduce$48.75 - $54
($51.57)
$ 53.293%Reduce -24.37%4,500
SNYJames Barrow 2013-09-30 Add1.29%$47.64 - $53.24
($50.87)
$ 53.295%Add 312.86%21,466,988
SNYMario Gabelli 2013-09-30 Add$47.64 - $53.24
($50.87)
$ 53.295%Add 32.22%5,950
SNYMario Gabelli 2013-06-30 Buy $49.77 - $55.64
($53.28)
$ 53.290%New holding, 4500 sh.4,500
SNYCharles Brandes 2013-06-30 Reduce-0.26%$49.77 - $55.64
($53.28)
$ 53.290%Reduce -20.35%1,713,266
SNYCharles Brandes 2012-09-30 Reduce-0.41%$36.81 - $44.6
($40.57)
$ 53.2931%Reduce -25.37%2,982,819
SNYDavid Dreman 2012-09-30 Sold Out -0.09%$36.81 - $44.6
($40.57)
$ 53.2931%Sold Out0
SNYJohn Hussman 2012-06-30 Add$33.4 - $39.06
($35.98)
$ 53.2948%Add 22.62%27,100
SNYPRIMECAP Management 2012-03-31 Add0.08%$35.32 - $38.92
($35.05)
$ 53.2952%Add 141.26%2,222,692
SNYJames Barrow 2011-12-31 Add0.08%$31.72 - $37.45
($34.48)
$ 53.2955%Add 26.83%4,501,475
SNYGeorge Soros 2011-12-31 Sold Out -0.11%$31.72 - $37.45
($34.48)
$ 53.2955%Sold Out0
SNYJames Barrow 2011-09-30 Add0.13%$31.5 - $40.08
($35.94)
$ 53.2948%Add 83.96%3,549,200
SNYGeorge Soros 2011-09-30 Buy 0.11%$31.5 - $40.08
($35.94)
$ 53.2948%New holding, 201400 sh.201,400
SNYDodge & Cox 2011-06-30 Add0.16%$35.68 - $40.58
($38.04)
$ 53.2940%Add 6.63%54,287,695
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SNY is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
SNY PRIMECAP Management 2014-06-303,011,6460.110.18+21.59%
SNY Charles Brandes 2014-06-302,182,3050.081.4+5.28%
SNY James Barrow 2014-06-3028,526,8021.082+2.65%
SNY Mario Gabelli 2014-06-304,50000
SNY Warren Buffett 2014-06-303,905,8750.150.19
SNY Dodge & Cox 2014-06-3043,549,9091.642.2-0.26%
SNY Jean-Marie Eveillard 2014-06-30608,5680.020.08-0.36%
SNY Scott Black 2014-06-30178,9850.011.4-27.57%
SNY John Hussman 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


SNY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sanofi10% Owner 2014-03-25Buy344,448$66.88-20.32view
Sanofi10% Owner 2014-02-04Buy1,303,780$7.67594.78view

Press Releases about SNY :

    Quarterly/Annual Reports about SNY:

      News about SNY:

      Articles On GuruFocus.com
      Evaluating MannKind (MNKD) & Sanofi (SNY) Agreement for Afrezza Aug 15 2014 
      George Soros Reveals His Largest Stake Jul 23 2014 
      Health Care Sector in an Upward Climb in June Jun 12 2014 
      Sarah Ketterer’s Causeway International Value’s Top Five Holdings Jun 05 2014 
      Top Held European Stocks Highlighted by Health Care and Oil and Gas Stocks May 29 2014 
      Oakmark's Bill Nygren Discusses Financials, Favorite Stocks Apr 15 2014 
      Bill Nygren Comments on Sanofi Apr 08 2014 
      Bill Nygren's Oakmark Fund First Quarter 2014 Commentary Apr 08 2014 
      Sanofi's Getting Back in the Game Mar 25 2014 
      Top Held European Stocks Highlighted by Health Care and Oil and Gas Stocks Mar 12 2014 


      More From Other Websites
      FDA Approves Genzyme’s Cerdelga™ (eliglustat) Capsules Aug 19 2014
      FDA Approves Genzyme’s Cerdelga™ (eliglustat) Capsules Aug 19 2014
      4:45 pm Sanofi-Aventis: FDA approves Genzyme's Cerdelga (eliglustat) capsules Aug 19 2014
      Eli Lilly-Boehringer's Insulin Drug Gets Tentative FDA Nod Aug 19 2014
      Washington Post Off Base In Critiquing Pharma Efforts In Ebola Aug 18 2014
      Merck's Insomnia Drug Belsomra Approved by the FDA Aug 14 2014
      Stock Market News for August 14, 2014 Aug 14 2014
      Why InterMune (ITMN) Stock Is Down Today Aug 14 2014
      Sanofi Pasteur Announces Publication of Positive Data for Fluzone® High-Dose Vaccine in The New... Aug 13 2014
      Sanofi Pasteur Announces Publication of Positive Data for Fluzone® High-Dose Vaccine in The New... Aug 13 2014
      Blame MannKind's Fall on its Bloated Balance Sheet Aug 13 2014
      What the Market is Telling MannKind Aug 13 2014
      Did MannKind Find Right Afrezza Partner in Sanofi? Aug 12 2014
      MannKind Posts Wider Q2 Loss, Up on Sanofi Deal for Afrezza Aug 12 2014
      Sanofi Launches Authorized Generic Version of Eloxatin® (oxaliplatin injection) Aug 12 2014
      First antimalarial treatments produced with semisynthetic artemisinin enter market Aug 12 2014
      MannKind Enters into a Global Deal with Sanofi for Afrezza Aug 11 2014
      [video] Sanofi to Pay MannKind as Much as $925M for Afrezza Global Rights Aug 11 2014
      Jim Cramer's Mad Dash: Good News for Tesla and MannKind Aug 11 2014
      MannKind shares soar on Sanofi deal; investors ignore earnings report Aug 11 2014
      MannKind Secures Future of Afrezza in Major Sanofi Deal Aug 11 2014
      Why ManKind (MNKD) Stock Is Soaring Today Aug 11 2014
      MannKind Shares Explode After Announcing Inhaled Insulin Deal Aug 11 2014
      Sanofi and MannKind Announce Global Licensing Agreement for Afrezza® (insulin human) Rapid-Acting... Aug 11 2014
      Sanofi and MannKind Announce Global Licensing Agreement for Afrezza® (insulin human) Rapid-Acting... Aug 11 2014
      Sanofi and MannKind Announce Global Licensing Agreement for Afrezza® (insulin human) Rapid-Acting... Aug 11 2014
      Online Availability of Sanofi Group’s Half-Year Financial Report for 2014 Aug 01 2014
      Solid sales and Business EPS growth at CER in Q2 2014 Jul 31 2014
      Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission Jul 30 2014
      Sanofi and Regeneron Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission Jul 30 2014
      Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in... Jul 30 2014
      Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in... Jul 30 2014
      First Ever Dengue Vaccine Candidate To Show Efficacy Against Dengue Fever and Dengue Haemorrhagic... Jul 11 2014
      Sanofi and Regeneron Announce Positive Results from Phase 2b Study of Dupilumab in Patients with... Jul 09 2014
      FDA Accepts Sanofi’s New Drug Application for Basal Insulin Toujeo® Jul 08 2014
      Sanofi and Regeneron To Present Alirocumab Clinical Data at American College of Cardiology 63rd... Mar 27 2014
      Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's... Mar 27 2014
      Sanofi Pasteur Allies with SK Chemical Co. of South Korea on Pneumococcal Conjugate Vaccine Mar 19 2014
      Sanofi and UCB Partner for Breakthrough Innovation in Immune-mediated Diseases Mar 11 2014
      Filing of the 2013 U.S. Form 20-F and French “Document de Référence” containing the Annual... Mar 07 2014
      Inactivated Polio Vaccines Broadly Available for the World’s Children in the Drive toward Polio... Feb 28 2014

      Add Notes, Comments or Ask Questions

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK
      Email Hide